BDBM224173 3-{6-(5- chloropyridin-3-yl)- 8-[(3r)-3-(2- fluorophenyl)morpho- lin-4-yl]-7-[(trans-4- methylcyclohexyl) methyl]-7h-purin-2-yl}- 1,2,4-oxadiazol- 5(4h)-one::US9540377, 16.92
SMILES: C[C@H]1CC[C@H](Cn2c(nc3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)N2CCOC[C@H]2c2ccccc2F)CC1
InChI Key:
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
p53-binding protein Mdm2 (Homo sapiens (Human)) | BDBM224173 (3-{6-(5- chloropyridin-3-yl)- 8-[(3r)-3-(2- fluoro...) | PDB GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.585 | n/a | n/a | n/a | n/a | n/a | 25 |
Merck Sharp & Dohme Corp. US Patent | Assay Description An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re... | US Patent US9540377 (2017) BindingDB Entry DOI: 10.7270/Q2RF5X1F | |||||||||||
More data for this Ligand-Target Pair |